Novartis AG - Product Pipeline Review - 2016

Date: March 22, 2016
Pages: 489
Price:
US$ 1,500.00 US$ 1,275.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: NCBAABC7E6CEN
Leaflet:

Download PDF Leaflet

Novartis AG - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Novartis AG - Product Pipeline Review - 2016’, provides an overview of the Novartis AG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Novartis AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the pipeline therapeutic landscape of Novartis AG
  • The report provides overview of Novartis AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Novartis AG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Novartis AG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Novartis AG’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Novartis AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Novartis AG’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Novartis AG Snapshot
Novartis AG Overview
Key Information
Key Facts
Novartis AG - Research and Development Overview
Key Therapeutic Areas
Novartis AG - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Novartis AG - Pipeline Products Glance
Novartis AG - Late Stage Pipeline Products
Novartis AG - Clinical Stage Pipeline Products
Novartis AG - Early Stage Pipeline Products
Novartis AG - Drug Profiles
ceritinib
dabrafenib mesylate + trametinib dimethyl sulfoxide
eltrombopag olamine
everolimus
serelaxin
trametinib dimethyl sulfoxide
zoledronic acid
imatinib mesylate
panobinostat
pazopanib hydrochloride
(glycopyrrolate + indacaterol maleate + mometasone fuorate)
(indacaterol maleate + mometasone furoate)
(sacubitril + valsartan)
alpelisib
bimagrumab
buparlisib hydrochloride
canakinumab
dabrafenib mesylate
fevipiprant
fingolimod hydrochloride
midostaurin
nilotinib
ofatumumab
osilodrostat phosphate
oxytocin
pasireotide
pasireotide ER
ranibizumab
ribociclib
secukinumab
siponimod
CDZ-173
clofazimine
CNP-520
(dectrekumab + VAK-694)
afuresertib hydrochloride
aldesleukin
BHQ-880
BVS-857
capmatinib
CFZ-533
cipargamin
CJM-112
dectrekumab
EGF-816
elgemtumab
EMA-401
FCR-001
GSK-2285921
HSC-835
iloperidone
infigratinib
KAF-156
KRP-203
LCL-161
LFX-453
LHW-090
ligelizumab
LJN-452
LMI-070
mavoglurant
MCS-110
octreotide acetate long acting
pradigastat sodium
ruxolitinib phosphate
selurampanel
sonidegib phosphate
tesidolumab
tisagenlecleucel-T
trametinib dimethyl sulfoxide + uprosertib
uprosertib
VAY-736
BZF-961
CGF-166
CSJ-137
CSJ-148
FGF-401
HDM-201
LAG-525
lapatinib ditosylate
MGB-453
PDR-001
PIM-447
RAF-265
sotrastaurin acetate
ABL-001
AV-380
Cellular Immunotherapy to Target c-Met for Oncology
Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia
Cellular Immunotherapy to Target EGFR for Glioblastoma
CGM-097
CLR-325
huCART19
IDH-305
IMP-701
LEQ-506
LGK-974
LML-134
LNA-043
LXH-254
LXS-196
MesoCART
NOV-10
NOV-11
NOV-7
NOV-8
NOV-9
octreotide acetate LAR
PBF-509
PCA-062
QCC-374
CART-123
Cellular Immunotherapy to Target B-Cell Maturation Factor for Multiple Myeloma
Antibody to Inhibit PD-L1 for Oncology
AUSRM-057
BLZ-945
BQS-481
BVB-808
Cellular Immunotherapy Program for Oncology
Cellular Immunotherapy to Target GD2 for Neuroblastoma
CHZ-868
cosyntropin ER
ESK-1
GNFPf-5069
Kartogenin
KR-22809
LCZ-960
LGB-321
LKZ-145
LQN-725
Monoclonal Antibody to Inhibit CXCR2 for Respiratory Diseases
NIBR-0213
NITD-349
NITD-916
NVPQBE-170
NVPTNKS-656
OXB-302
RP-6503
Small Molecule to Agonize GPR119 for Type 2 Diabetes
Small Molecule to Agonize GPR39 for Type 2 Diabetes
Small Molecule to Agonize Nurr1 for Multiple Sclerosis
Small Molecule to Inhibit LRRK2 for Parkinson's Disease
Small Molecule to Inhibit OX2R for Insomnia
Small Molecules to Antagonize VEGFR2 for Solid Tumors
Small Molecules to Inhibit Cytochrome bc1 Complex for Tuberculosis
Small Molecules to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer
Small Molecules to Inhibit Pan-RAF Kinase for Oncology
Small Molecules to Inhibit Renin for Hypertension
XOMA-089
ESBA-903 SR
LJH-685
Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology
Small Molecule to Agonize Adrenergic Beta-2 Receptor for COPD
Small Molecules for Tuberculosis
Small Molecules for Undisclosed Indication
Small Molecules to Antagonize NR2B for Depression
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Metabolic, Cardiovascular and Infections
Small Molecules to Inhibit CFTR for Secretory Diarrhea
Small Molecules to Inhibit FPPS for Soft Tissue Cancer
Small Molecules to Inhibit PfATP4 for Malaria
Small Molecules to Inhibit PI4KIIIbeta for HCV
Novartis AG - Pipeline Analysis
Novartis AG - Pipeline Products by Target
Novartis AG - Pipeline Products by Route of Administration
Novartis AG - Pipeline Products by Molecule Type
Novartis AG - Pipeline Products by Mechanism of Action
Novartis AG - Recent Pipeline Updates
Novartis AG - Dormant Projects
Novartis AG - Discontinued Pipeline Products
Novartis AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Novartis AG - Company Statement
Novartis AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Novartis AG, Key Information
Novartis AG, Key Facts
Novartis AG - Pipeline by Indication, 2016
Novartis AG - Pipeline by Stage of Development, 2016
Novartis AG - Monotherapy Products in Pipeline, 2016
Novartis AG - Combination Treatment Modalities in Pipeline, 2016
Novartis AG - Partnered Products in Pipeline, 2016
Novartis AG - Partnered Products/ Combination Treatment Modalities, 2016
Novartis AG - Out-Licensed Products in Pipeline, 2016
Novartis AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
Novartis AG - Pre-Registration, 2016
Novartis AG - Filing rejected/Withdrawn, 2016
Novartis AG - Phase III, 2016
Novartis AG - Phase II, 2016
Novartis AG - Phase I, 2016
Novartis AG - Phase 0, 2016
Novartis AG - Preclinical, 2016
Novartis AG - Discovery, 2016
Novartis AG - Pipeline by Target, 2016
Novartis AG - Pipeline by Route of Administration, 2016
Novartis AG - Pipeline by Molecule Type, 2016
Novartis AG - Pipeline Products by Mechanism of Action, 2016
Novartis AG - Recent Pipeline Updates, 2016
Novartis AG - Dormant Developmental Projects,2016
Novartis AG - Discontinued Pipeline Products, 2016
Novartis AG, Subsidiaries

LIST OF FIGURES

Novartis AG - Pipeline by Top 10 Indication, 2016
Novartis AG - Pipeline by Stage of Development, 2016
Novartis AG - Monotherapy Products in Pipeline, 2016
Novartis AG - Combination Treatment Modalities in Pipeline, 2016
Novartis AG - Partnered Products in Pipeline, 2016
Novartis AG - Out-Licensed Products in Pipeline, 2016
Novartis AG - Pipeline by Top 10 Target, 2016
Novartis AG - Pipeline by Top 10 Route of Administration, 2016
Novartis AG - Pipeline by Top 10 Molecule Type, 2016
Novartis AG - Pipeline Products by Top 10 Mechanism of Action, 2016
Skip to top


Ask Your Question

Novartis AG - Product Pipeline Review - 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: